期刊文献+

Telitacicept as a novel treatment for refractory lupus nephritis complicated by podocytic infolding glomerulopathy

原文传递
导出
摘要 To the Editor,Lupus nephritis(LN),a renal symptom of systemic lupus erythematosus(SLE),frequently causes severe organ damage in SLE patients.1 There is no consensus on the definition of refractory LN,which has been suggested to occur when remission is not achieved after 3–12 months of combined glucocorticoids and immunosuppressive therapy.2 Podocytic infolding glomerulopathy(PIG),a rare type of glomerular morphological alteration,is primarily characterized by the presence of microspheres,microtubular structures,or a combination of the two,which are associated with podocyte infolding into the glomerular basement membrane(GBM).3,4 The exact pathogenesis of PIG remains unclear,but it may be associated with autoimmune diseases like SLE and Sjögren's syndrome.The occurrence of refractory LN complicated by PIG is rare and poses significant challenges in management.Here,we endeavor to provide the patient with benefits by employing a novel treatment,Telitacicept,which has demonstrated the potential to achieve complete renal remission in such cases.
出处 《Rheumatology & Autoimmunity》 2024年第3期186-188,共3页 风湿病与自身免疫(英文)
基金 National Key Research and Development Program of China(2021YFC2501304) Science and Technology Program of Department of Health of Jiangxi Province(20204254) Key Research and Development Program of Jiangxi Municipal Science and Technology Department(20192BBGL70024).
关键词 NEPHRITIS LUPUS LUPUS
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部